Stay updated on Pembrolizumab in Thymic Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Thymic Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Thymic Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. A funding-status notice and the previous v3.4.1 revision were removed; these are administrative updates that do not affect study data or how to use the page.SummaryDifference0.5%

- Check21 days agoChange DetectedDifference0.5%

- Check28 days agoChange DetectedThe page now shows a glossary and the metadata revision is updated to v3.4.0, with minor capitalization changes in labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check42 days agoChange DetectedFooter revision updated from v3.3.3 to v3.3.4; no content or functionality was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedSite maintenance notes show Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure (previous Revision: v3.3.2); no study details or data are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedPublications section now notes that entries are automatically filled from PubMed and displays Revision: v3.3.2. The previous wording about PubMed-derived publications has been replaced with updated phrasing.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Thymic Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Thymic Tumors Clinical Trial page.